Search details
1.
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Cell
; 183(6): 1714-1731.e10, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-33275901
2.
Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Chembiochem
; 24(19): e202300141, 2023 10 04.
Article
in English
| MEDLINE | ID: mdl-37088717
3.
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Nat Chem Biol
; 12(10): 876-84, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27571479
4.
Human Polo-like Kinase Inhibitors as Antiplasmodials.
ACS Infect Dis
; 9(4): 1004-1021, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-36919909
5.
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Cell Chem Biol
; 30(6): 618-631.e12, 2023 06 15.
Article
in English
| MEDLINE | ID: mdl-37290440
6.
Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
J Med Chem
; 63(13): 6708-6726, 2020 07 09.
Article
in English
| MEDLINE | ID: mdl-32502343
7.
Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Cell Chem Biol
; 27(5): 525-537.e6, 2020 05 21.
Article
in English
| MEDLINE | ID: mdl-32130941
8.
NUAK2 is a critical YAP target in liver cancer.
Nat Commun
; 9(1): 4834, 2018 11 16.
Article
in English
| MEDLINE | ID: mdl-30446657
9.
Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors.
Cell Chem Biol
; 25(2): 135-142.e5, 2018 02 15.
Article
in English
| MEDLINE | ID: mdl-29276047
10.
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Elife
; 72018 11 13.
Article
in English
| MEDLINE | ID: mdl-30422115
11.
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
ACS Chem Biol
; 13(9): 2438-2448, 2018 09 21.
Article
in English
| MEDLINE | ID: mdl-30102854
Results
1 -
11
de 11
1
Next >
>>